Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion.: Apoptosis and regulatory T cells by Kleinclauss, François, et al.
Intravenous apoptotic spleen cell infusion induces a
TGF-beta-dependent regulatory T-cell expansion.
Franc¸ois Kleinclauss, Sylvain Perruche, Emeline Masson, Marcelo De Carvalho
Bittencourt, Sabeha Biichle, Jean-Paul Remy-Martin, Christophe Ferrand,
Mael Martin, Hugues Bittard, Jean-Marc Chalopin, et al.
To cite this version:
Franc¸ois Kleinclauss, Sylvain Perruche, Emeline Masson, Marcelo De Carvalho Bittencourt,
Sabeha Biichle, et al.. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent
regulatory T-cell expansion.: Apoptosis and regulatory T cells. Cell Death and Differentia-
tion, Nature Publishing Group, 2006, 13 (1), pp.41-52. <10.1038/sj.cdd.4401699>. <inserm-
00473141>
HAL Id: inserm-00473141
http://www.hal.inserm.fr/inserm-00473141
Submitted on 20 Feb 2012
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 1 
Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T 
cell expansion 
François Kleinclauss
1-5
, Sylvain Perruche
1-4
, Emeline Masson
1-4
, Marcelo de Carvalho 
Bittencourt
1-4
, Sabeha Biichle
1-4
, Jean-Paul Remy-Martin
1-4
, Christophe Ferrand
1-4
, Mael 
Martin
5
, Hugues Bittard
4,5
, Jean-Marc Chalopin
1,2,4,6
, Estelle Seilles
1-4
, Pierre Tiberghien
1-4
, 
Philippe Saas
1-4*
 
 
1
INSERM U645, Besançon, F-25020 France; 
2
Univ Besançon, Besançon, F-25020 France; 
3
EFS BFC, Besançon, F-25020 France; 
4
IFR 133; Besançon, F-25000 France; 
5
CHU 
Besançon, Service d’Urologie, Besançon, F-25000 France; 6Service de Néphrologie, 
Besançon, F-25000 France. 
 
F Kleinclauss and S Perruche contributed equally to this work 
MCB Current address: INSERM UMR433, Laboratoire de Virologie-Immunologie, CHRU 
Fort de France, F-97261, Martinique 
 
*Corresponding author: P Saas, INSERM U645/EA 2284/EFS Bourgogne Franche-Comté, 1 
Bd A Fleming, BP1937, F-25020 Besançon, France. Tel: 33 3 81 61 56 15; FAX: 33 3 81 61 
56 17; E-mail: philippe.saas@efs.sante.fr 
 
Running title: Apoptosis and regulatory T cells 
 
Categories: (6) Immunity/Inflammation 
Abstract word count: 151 
 2 
Abstract 
Apoptotic leukocytes are endowed with immunomodulatory properties that can be used to 
enhance hematopoietic engraftment and prevent graft-versus-host disease. This apoptotic cell-
induced tolerogenic effect is mediated by host macrophages and not recipient dendritic cells 
or donor phagocytes present in the bone marrow graft as evidenced by selective cell depletion 
and trafficking experiments. Furthermore, apoptotic cell infusion is associated with TGF-β-
dependent donor CD4
+
CD25
+
 T cell expansion. Such cells have a regulatory phenotype 
(CD62L
high
 and intracellular CTLA-4
+
), express high levels of Foxp3 mRNA and exert ex 
vivo suppressive activity through a cell-to-cell contact mechanism. In vivo CD25 depletion 
after apoptotic cell infusion prevents the apoptotic spleen cell-induced beneficial effects on 
engraftment and graft-versus-host disease occurrence. This highlights the role of regulatory T 
cells in the tolerogenic effect of apoptotic spleen cell infusion. This novel association between 
apoptosis and regulatory T cell expansion may also contribute to preventing deleterious auto-
immune responses during normal turnover. 
 
Keywords: Transplantation; macrophages; apoptosis; regulatory T cells 
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Abbreviations: Ab, antibody; APC, allophycocyanin; BM, bone marrow; BMT, bone 
marrow transplantation; CDC, complement-dependent cytotoxicity; DC, dendritic cells; DT, 
diphtheria toxin; Foxp3, forkhead-box transcription factor p3; GvHD, graft-versus-host 
disease; HC, hematopoietic cell; mAb, monoclonal antibody; MLR, mixed leukocyte reaction; 
PerCP, peridinin chlorophyll-a protein; QRT-PCR, quantitative real time PCR; TBI, total 
body irradiation; Tr1, T regulatory type 1 cells; Treg, regulatory T cells 
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Introduction 
Immune tolerance is maintained by several mechanisms.
1
 In addition to central tolerance, 
various peripheral mechanisms, including T cell anergy or peripheral T cell deletion, 
cooperate to prevent unwanted T cell immune responses directed against self antigens.
1
 
Recently, active suppression by CD4
+
CD25
+
 regulatory T cells (Treg) has been extensively 
explored as a mechanism involved in limiting auto-immunity
2,3
 as well as a way to induce 
transplantation tolerance.
4
 Thus, CD4
+
CD25
+
 Treg cells have been shown to prevent acute 
graft-versus-host disease (GvHD),
5,6
 a frequent complication of allogeneic hematopoietic cell 
(HC) transplantation. Expression of CD25 is shared by different CD4
+
 Treg subsets including 
CD4
+
CD25
+
 "suppressive" T cells which act by cell contact-dependent mechanisms,
3,7
 IL-10 
producing T regulatory type 1 (Tr1) cells
8
 and TGF- producing Th3 cells.9 Other Treg-
associated molecules such as CD62L or CTLA-4 (CD152) are commonly used to identify 
CD4
+
 Treg cells.
4,5
 Recently, forkhead-box transcription factor p3 (Foxp3, called also scurfin) 
has emerged as an adequate marker for "natural" CD4
+
CD25
+
 "suppressive" T cells
10-12
 as 
well as other peripherally produced CD4
+
 T cells endowed with regulatory properties.
13-15
 
However, the phenotypic characterization as well as suppressive mechanism of CD4
+
 Treg 
cells may differ, depending on the experimental model used.
3
 
 
Apoptosis is a physiological process which liberates intracellular proteins, rendering critical 
the maintenance of self-tolerance. Thus, following normal cellular turnover, billions of 
apoptotic cells are produced every day without systematically causing autoimmunity. Several 
peripheral tolerance mechanisms explaining the absence of immune responses against 
apoptotic cell-derived Ags have been proposed.
16-18
 First, professional phagocytes, such as 
macrophages
19
 or certain dendritic cells (DC) subsets,
20-23
 quickly capture apoptotic bodies, 
thereby preventing the release of harmful products from dying cells.
24
 In addition, apoptotic 
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cell death is frequently associated with an immunomodulatory milieu that may neutralize 
immune cells present in the environment of dying cells. Such milieu consists mainly of anti-
inflammatory cytokines like IL-10 or TGF- released by macrophages which phagocyte 
apoptotic cells
19,25,26
 or by circulating monocytes in the absence of phagocytosis.
27
 
Furthermore, some cells like T cells may release TGF- or IL-10 in the course of their 
apoptotic process.
28,29
 Although the release of TGF- or IL-10 during apoptosis has been 
extensively reported,
19,25-29
 capacities of apoptotic cells to induce a CD4
+
 T cell subset 
endowed with regulatory properties has not been demonstrated so far. 
 
Allogeneic HC transplantation is characterized by the presence of immunocompetent cells of 
both host and donor origin and the subsequent alloreactive conflict. Donor graft rejection is 
mainly mediated by recipient T or NK cells that resist the conditioning regimen. In contrast, 
donor immune cells present in the HC graft are responsible for inducing GvHD. In some 
situations, GvHD can be beneficial to the host by limiting leukemia relapse (graft-versus-
leukemia effect). Strategies are required to control this alloreactive conflict that follows 
allogeneic HC transplantation. Physiological mechanisms that maintain immune homeostasis 
and self-tolerance have been exploited for a long time to induce tolerance to allograft.
30
 In this 
way, we used i.v. infusion of apoptotic leukocytes to enhance bone marrow (BM) engraftment 
across major histocompatibility barriers whatever their origin.
31
 Here, we reported that after 
infusion, apoptotic spleen cells were engulfed by splenic dendritic cells and macrophages. 
Depletion of donor phagocytes present in the graft had no effect on apoptotic cell–induced 
engraftment. Conversely, depletion of host macrophages –but not host dendritic cells– before 
transplantation prevented apoptotic spleen cell-induced engraftment. Furthermore, apoptotic 
spleen cell infusion was associated with donor CD4
+
CD25
+
 T cell expansion which depends 
on TGF-production. Such cells had a regulatory phenotype (CD62L+, intracellular CTLA4+) 
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and expressed high levels of Foxp3 mRNA. Ex vivo, these Treg exerted their suppressive 
activity through a cell-to-cell contact mechanism independently of IL-10 or TGF-. In vivo, 
these Treg were involved in the protective effect of donor apoptotic spleen cell administration 
on GvHD occurrence.
 7 
RESULTS 
The graft-facilitating effect of apoptotic spleen cell infusion requires host macrophages 
but not donor phagocytes present in the bone marrow graft. 
Apoptotic cells are quickly removed by macrophages
19,26
 or some DC subsets.
20-23
 To 
examine which cell populations would engulf apoptotic cells, recipients were given donor 
fluorescent-labeled apoptotic spleen cells in addition to the BM graft. At various times post-
BMT (30, 45 min, 1, 2, 4 and 8 h), the spleen, liver and lungs were analyzed to determine 
where and by which phagocytes apoptotic cells had been engulfed. Analysis of time kinetics 
revealed that apoptotic spleen cells were quickly removed mainly by splenic phagocytes, 
since there was no detectable fluorescent signal in the lung or in the liver at any time points 
after infusion (data not shown). Flow cytometric analysis indicated that splenic DC as well as 
macrophages were involved in apoptotic cell uptake (Figure 1a). A higher proportion of 
labeled phagocytes was observed 45 min after infusion, while no signal could be detected in 
the spleen tested 4 h after infusion (Figure 1a). Phagocytes involved in apoptotic spleen cell 
uptake may be resident host splenic phagocytes and/or phagocytes present in donor BM graft 
that migrate to the spleen after infusion. To evaluate the involvement of donor phagocytes, an 
enriched Sca-1
+
 stem cell graft (3 x 10
5
 cells) was used instead of a total BM graft. Despite 
significant depletion of CD11c
+
 cells (83 + 8%) and F4/80
+
 cells (95 + 9%) after Sca-1
+
 cell 
enrichment, donor HC engraftment was conserved (Figure 1b). This suggests that donor 
phagocytes are not required for the graft facilitating effect of apoptotic spleen cells. 
To deplete resident host phagocytes, liposomes loaded with clodronate
32, 33
 were infused 
before BMT. Pretreatment of mice with clodronate-loaded liposomes reduced significantly 
both the number of splenic CD11b
+
 macrophages and apoptotic cell-induced donor BM 
engraftment (Figure 1c). As previously described,
33
 we observed that not all splenic DC 
subsets were depleted by clodronate-loaded liposome infusion due to their anatomic location 
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(Supplementary Figure 1 online). To further explore the role of host DC in the graft-
facilitating effect of apoptotic cells, a transgenic mouse model for in vivo DC ablation
34
 was 
used. Administration of diphtheria toxin (DT) in such recipient transgenic mice allowed 
splenic DC depletion for 48 h (Figure 1d and ref.34). Despite significant depletion of 
eGFP
+
CD11c
+
 DC at the time of BMT, the graft-facilitating effect of apoptotic cells was 
maintained (Figure 1d). This suggests that host DC are not critical for the graft-facilitating 
effect induced by apoptotic spleen cell infusion. Altogether, these results show that recipient 
splenic phagocytes and in particular macrophages are involved in the graft-facilitating effect 
of i.v. apoptotic cell infusion. 
 
Intravenous apoptotic spleen cell infusion leads to the TGF-β dependent expansion of 
CD4
+
CD25
+
 regulatory T cells. 
We recently reported that i.v. administration of apoptotic spleen cells, simultaneously with 
BM grafts, favored engraftment via a TGF--dependent mechanism.35 Because TGF- can be 
implicated in the generation of Treg sub-populations
9,13-15
 and as fluorescent apoptotic bodies 
within splenic phagocytes could be found (Figure 1a), we first analyzed the spleen for the 
presence of CD4
+
CD25
+
 T cells at week 7-9 post-BMT. Analysis of splenic T cell populations 
in mice given apoptotic cells revealed a CD4
+
CD25
+
 T cell increase in engrafted versus non-
engrafted recipients (8.8 + 0.6% vs. 3.9 + 0.4%, mean + SEM, 10 mice per group, P < 0.01, 
Figure 2a). All these recipient mice exhibited a similar splenic cellularity (between 70-100 x 
10
6
 cells). Expansion of CD4
+
CD25
+
 T cells was restricted to engrafted mice and specific to 
apoptotic cell infusion, since no such increase was observed in recipient mice engrafting after 
infusion of a higher number of BM cells (3 x 10
6
 BM cells, 1.0 + 0.2%, n = 8, P < 0.05) or 
after an increased conditioning regimen (total body irradiation, TBI dose: 7 Gy, 1.5 + 0.2%, n 
= 5, P < 0.05) in the absence of apoptotic cells (Figure 2a). Such CD4
+
CD25
+
 T cell increase 
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observed 7-9 weeks after apoptotic cell infusion was not systematically found in the blood 
nor in other organs tested, including BM, cervical as well as inguinal lymph nodes (data not 
shown). To determine the role of TGF-β in this apoptotic cell-induced increase, CD4+CD25+ 
T cells were analyzed at week 7-9 after BMT and TGF-β neutralization. Mice treated with 
anti-TGF-β antibody (Ab) did not exhibit any increase in splenic CD4+CD25+ T cells (Figure 
2b). In contrast, mice given irrelevant Ab plus apoptotic cells had similar splenic CD4
+
CD25
+
 
T cell levels as mice receiving apoptotic cells (Figure 2b). TGF-β neutralizing effect could be 
also observed in peripheral blood (62 + 7 CD4
+
CD25
+
 T cells/µL in anti-TGF- Ab treated 
mice vs 288 + 46 cells/µL in control Ab-treated mice; P < 0.01). Overall, this suggests that 
TGF-β production is involved in apoptotic cell-induced CD4+CD25+ T cell increase. 
Further phenotypic and functional characterization of splenic CD4
+
CD25
+
 T cells detected in 
mice given apoptotic spleen cells was performed to know whether such cells displayed 
regulatory functions. The CD4
+
CD25
+
 T cells present in engrafted mice were of donor origin; 
they presented a regulatory T cell-like phenotype (CD45RB
low
CD62L
high
 intracellular CTLA-
4
high
) and expressed high levels of Foxp3 mRNA (Figure 3a-b). In contrast, CD4
+
CD25
+
 T 
cells found in non-engrafted mice exhibited a phenotype rather consistent with an activated T 
cell phenotype (intracellular CTLA-4
low
, CD62L
low
) and were, as expected, of host origin 
(Figure 3a). Purified CD4
+
CD25
+
 T cells from non-engrafted mice expressed low levels of 
Foxp3 mRNA (Figure 3b). Increase of splenic CD4
+
CD25
+
 T cells 7-9 weeks after apoptotic 
cell infusion was confirmed by direct quantification of FoxP3 mRNA in recipient whole 
spleen. A 9-fold increase of FoxP3 mRNA expression was detected at week 7-9 after BMT in 
mice given apoptotic cells plus BM in comparison to mice given BM alone (Figure 3c). 
Finally, CD4
+
CD25
+
 T cells were functionally characterized in in vitro assays. CD25 
depletion restored allogeneic proliferation of splenic CD4
+
 T cells from engrafted mice that 
had received apoptotic spleen cells, whereas CD25 depletion did not affect the proliferation of 
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splenic CD4
+
 T cells from non-engrafted mice (Figure 3d). In addition, suppressive assays 
with FACS-sorted CD4
+
CD25
+
 T cells demonstrated that apoptotic cell-induced CD4
+
CD25
+
 
T cells exerted their suppressive activity through cell contact-dependent mechanisms. Their 
suppressive activity could only be inhibited by adding a transwell but not by IL-10, TGF-, or 
IL-10 and TGF- neutralization (Figure 3e). These results show that simultaneous apoptotic 
spleen cell and BM infusion induced a TGF-β-dependent splenic expansion of 
CD62L
high
CD4
+
CD25
+
 T cells endowed with regulatory properties at week 7-9 after BMT. 
 
Host macrophage but not dendritic cell depletion is critical for the induction of splenic 
CD62L
+
CD4
+
CD25
+
 T cells after apoptotic spleen cell infusion. 
We then considered which host cells phagocyting apoptotic cells (macrophages and/or DC) 
were responsible for splenic CD62L
high
CD4
+
CD25
+
 T cell induction. Effects of DC depletion 
at time of transplantation were analyzed in CD11c/DTR/eGFP transgenic recipient. No 
significant modification of CD62L
high
C4
+
CD25
+
 T cell population was observed when DC 
were depleted at time of transplantation in comparison to non-CD11c depleted transgenic 
mice, even after apoptotic spleen cell infusion (Figure 4). Clodronate-liposome infusion at 
the time of BMT and apoptotic cell infusion induced the failure of both BM engraftment and 
donor CD4
+
CD25
+
 T cell expansion (data not shown). It was thus difficult to know whether 
donor CD4
+
CD25
+
 T cells participated to BM engraftment or whether donor 
CD62L
+
CD4
+
CD25
+
 T cell increase was related to BM engraftment. To answer to this 
question, splenic CD62L
high
CD4
+
CD25
+
 T cells were analyzed by cytometry at different early 
time points after BMT and macrophage depletion (using clodronate-loaded liposome). This 
phenotype (CD62L
+
CD4
+
CD25
+
) was chosen since we showed that cells with such phenotype 
express high levels of Foxp3 mRNA (Figure 3b) and exert suppressive activity (Figure 3d-
e). Early after apoptotic spleen cell infusion (day 6 and day 8 after BMT), a significant 
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increase of CD62L
+
CD4
+
CD25
+
 T cells was observed in the spleen (Figure 5a). This increase 
was not found in irradiated mice (data not shown), in mice receiving BM alone as well as in 
mice pretreated with clodronate-loaded liposomes before apoptotic spleen cell and BM 
infusion (Figure 5a). This shows that macrophage depletion prevents apoptotic spleen cell-
induced CD62L
+
CD4
+
CD25
+
 T cell increase. In addition, these experiments showed that 
increase of splenic CD62L
+
CD4
+
CD25
+
 T cells was detected early in all mice receiving 
apoptotic cells independently of whether they engrafted or not and that this increase 
implicated both donor and recipient CD62L
+
CD25
+
CD4
+
 T cells (Figure 5b). This suggests 
that the CD62L
+
CD4
+
CD25
+
 T cell increase is independent of BM engraftment and that these 
cells are induced peripherally after apoptotic cell infusion in the presence of recipient 
macrophages. 
 
In vivo CD25 depletion after donor apoptotic spleen cell infusion limits the graft 
facilitating effect of apoptotic cells. 
To determine the role of splenic CD62L
+
CD4
+
CD25
+
 T cell expansion after apoptotic spleen 
cell infusion, anti-CD25 monoclonal antibody (mAb) was infused at day 0 and day 3 after 
BMT and engraftment was evaluated at week 7 post-BMT. Despite a significant reduction of 
peripheral blood CD4
+
CD25
+
 T cells one week after BMT (227 + 25 cells/µL in irrelevant 
mAb treated mice vs. 12 + 3 cells/µL in CD25 treated mice), the administration of anti-CD25 
mAb did not significantly alter the proportion of engrafted mice 7-9 weeks post-BMT (50% 
vs. 42% in mice having received irrelevant mAb, Figure 6). However, CD25 depletion 
significantly decreased the levels of circulating donor-derived cells in engrafted mice at time 
of engraftment analysis (24.8 + 6.4% donor cells after anti-CD25 mAb administration vs. 72 
+ 15% after control mAb treatment, P < 0.05; Figure 6). This result was not surprising since 
CD25 is not a specific marker of Treg and is expressed by activated T cells.
4
 Thus, anti-CD25 
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mAb might deplete both apoptotic cell-induced recipient and donor-derived Treg as well as 
host activated T cells that limit engraftment. This latter effect could favor donor engraftment 
explaining why similar proportions of engrafted mice were found after CD25 depletion. 
Altogether with kinetic studies showing an early increase of CD62L
+
CD4
+
CD25
+
 T cells after 
apoptotic cell infusion, these in vivo results suggest that CD62L
+
CD4
+
CD25
+
 T cells are 
involved in the graft facilitating effect observed after apoptotic spleen cell infusion. 
 
Regulatory T cell expansion is involved in the protective effect of donor apoptotic spleen 
cell administration on graft-versus-host disease occurrence 
Apoptotic spleen cell-induced Treg expansion may also be implicated in prevention of GvHD. 
We have therefore studied the effects of donor apoptotic spleen cell infusion in an 
experimental model of GvHD. BALB/c recipient mice were lethally irradiated and the 
following day received a graft containing donor BM cells plus viable donor splenic T cells (to 
induce GvHD) with or without apoptotic spleen cells from the BM donor origin. Apoptotic 
cell infusion significantly delayed the onset of lethal GvHD in a dose-dependent manner 
(Figure 7a-b). We then addressed whether donor CD4
+
 CD25
+
 T cells expansion was 
involved in this delayed GvHD lethality observed after donor apoptotic spleen cell infusion. 
Depleting anti-CD25 mAb was administrated at days 3 and 6 post-BMT. This treatment 
abolished completely the protective effect of donor apoptotic cell infusion on GvHD (Figure 
7c). Overall, these data strongly suggest that donor apoptotic spleen cell infusion induces the 
expansion of donor-derived CD4
+
 CD25
+
 Treg minimizing anti-recipient immune responses 
involved in GvHD lethality. 
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Discussion 
New therapeutic approaches are required to modulate alloreactivity in HC transplantation. We 
recently described an alternative cell-based therapy using i.v. apoptotic leukocyte infusion to 
favor BM engraftment across MHC barriers.
31,35
 We have previously shown that the apoptotic 
feature only and not the cell origin is implicated in favoring BM engraftment.
31
 Here, we 
provide evidence that i.v. infused apoptotic spleen cells were quickly captured by host splenic 
macrophages and DC. Donor phagocytes present in the BM graft were not implicated in the 
graft facilitating effect of apoptotic spleen cell infusion. In contrast, depletion of host 
macrophages –but not host dendritic cells– before transplantation prevented apoptotic cell-
induced engraftment. Furthermore, apoptotic spleen cell infusion was associated with donor 
Treg expansion. Ex vivo, these Treg exerted their suppressive activity through a cell-to-cell 
contact mechanism independently of IL-10 or TGF-. Both host macrophages and TGF-β 
production were implicated in this splenic Treg expansion. In vivo CD25-depletion after 
donor apoptotic spleen cell infusion reduced the rate of donor-derived cells and prevented the 
protective effect of donor apoptotic cell administration on GvHD occurrence. Altogether, 
these in vivo results confirm that Treg induced by the simultaneous infusion of donor 
apoptotic spleen cells and allogeneic grafts are involved in the immunomodulatory effects of 
such apoptotic cells on alloreactivity. 
 
Apoptotic cells are endowed with immunomodulatory properties.
16,17
 Macrophages involved 
in apoptotic cell capture have been described to release TGF-β both in vitro19 and in vivo.26 A 
previous in vitro study reported that TGF-β was specifically released by macrophages 
ingesting apoptotic cells but not during any other type of phagocytosis.
19
 TGF-β production is 
due mainly to the ligation of phosphatitylserines exposed on apoptotic cells to their receptor 
expressed on macrophages.
36
 This immunomodulatory milieu created by macrophages 
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participated in the neutralization of unwanted immune responses against apoptotic cell 
derived Ag.
16,26
 This may explain why autoimmunity is controlled although billions of cells 
die during physiological turnover. Moreover, we have reported the absence of autoimmunity 
after long-term follow-up of mice that had received a single infusion of apoptotic spleen cells 
simultaneously with their BM grafts.
37
 TGF-β was reported by several groups to induce 
CD4
+
CD25
+
 T cells endowed with regulatory functions.
13-15
 Several CD4
+
CD25
+
 T cell 
subsets have been described to exert regulatory functions.
2-4
 Sagakuchi's group first 
demonstrated that CD4
+
 T cells expressing CD25 molecules controlled autoimmunity in naive 
mice.
2
 Here, we strongly suggest a direct link between macrophages, apoptotic spleen cell 
uptake, TGF-β and Treg-like cell expansion. This Treg induction after massive apoptotic 
primary tissue cell death –that was mimicked in our model by i.v. infusion of five millions of 
apoptotic spleen cells may constitute an additional mechanism that takes over from TGF-β 
secretion to maintain homeostasis. Since TGF- activation from TGF-β latent complex is 
known to be tightly regulated and lead to a transient effect restricted to neighbor cells,
38
 Treg 
expansion after massive apoptotic cell death may be responsible for long-term autoimmunity 
control (either locally or in other sites). Interestingly, induction of Treg cells in the spleen 
after random blood product transfusion has been previously reported
39
 and non-specific 
immunomodulatory effects of preoperative blood product transfusion has been proposed to be 
related to the presence of apoptotic leukocytes present in stored blood products.
16,40,41
 The 
immunomodulatory role of apoptotic leukocytes can be also extended to the prevention of 
allo-immune responses. Sun et al. have recently reported that i.v. infusion of donor apoptotic 
spleen cells prolongs heart allograft survival. Interestingly, these authors demonstrated that 
this effect required phagocytosis by host cells.
42
 We reported that apoptotic spleen cell 
infusion with an allogeneic graft prevented anti-BM donor allo-immunization even in mice 
rejecting their grafts.
35
 Treg expansion after apoptotic cell infusion could be beneficial for 
 15 
engraftment as well as to the host (i.e., absence of anti-donor immunization or GvHD 
control). 
 
Dendritic cell subsets have also been implicated in apoptotic cell uptake
17,20-23
 and subsequent 
T cell cross-tolerization.
20-22
 In our model, we found fluorescent apoptotic bodies in splenic 
DC, suggesting that apoptotic cell-derived Ag can also be processed by some DC subsets. 
However, selective DC depletion did not significantly affect either the graft-facilitating effect 
or splenic Treg expansion after apoptotic spleen cell infusion. Macrophages were thus 
sufficient to uptake apoptotic cells and possibly released TGF- after phagocytosis.19,26 
Macrophages were more efficient than immature DC to uptake apoptotic cells
43
 and were 
found in higher numbers than DC in the spleen. Macrophages may create an 
immunomodulatory milieu that neutralizes DC Ag-presenting functions. TGF-β has been 
reported to inhibit the ability of DC to present antigen, stimulate IFN-γ production by T cells, 
and migrate to draining lymph nodes.
44
 Our model made it possible to determine in vivo the 
respective implications of macrophages and DC after massive apoptotic leukocyte death in an 
inflammatory situation (i.e., after TBI): macrophages appear as the key players. This sustains 
the results of Sun et al..
42
 
 
The thymus and the periphery (i.e., where regulation takes place) are both involved in 
generating Treg. Regulatory T cells induced by apoptotic cell infusion can be generated from 
a conversion of peripheral naive CD4
+
 T cells into a regulatory phenotype or by an increased 
production of natural suppressive T cells after engraftment. In our model, several arguments 
are in favor of the first hypothesis: preferential expansion in the spleen (where fluorescent 
apoptotic bodies were found), early induction of both donor and recipient populations (as 
attested by kinetic studies) and TGF- dependency. Regulatory CD4+ T cells induced by in 
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vitro TGF- exposure arise from "conventional" naive CD4+CD25- T cell precursors.13-15 
They acquire Foxp3 mRNA expression and exert their suppressive activity mainly through 
TGF-.13-15 In our study, despite TGF- dependency of Treg induction, such cells induced 
after apoptotic cell infusion expressed high levels of Foxp3 mRNA and exerted ex vivo 
suppressive activities mainly through a cell contact-dependent activity. However, we cannot 
exclude that the observed Treg exert their activity through membrane-bound TGF-. 
Membrane TGF neutralization with mAb is indeed not easy to perform.
7
 Human and murine 
Treg generated in the periphery from naive CD25
-
CD4
+
 T cells can exert suppression trough a 
cell-to-cell contact dependent and cytokine-independent mechanism.
45-47
 Such findings 
suggest that apoptotic cell-induced Treg that exert cell-to-cell suppression are generated 
peripherally from CD4
+
 T cells in the presence of TGF-β. "Spontaneous" conversion of 
CD4
+
CD25
-
 T cells into CD62L
+
 Foxp3 mRNA
+
 Treg after in vivo transfer in syngeneic 
irradiated recipient has been recently reported.
45
 Thus, in vivo administration of apoptotic 
cells at time of infusion of CD4
+
 T cells may increase the conversion of such cells into Treg. 
 
Increased BM engraftment linked to Treg induction has only been recently reported.
48-50
 For 
example, CD8
+
TCR
-
 facilitating cells, derived from BM, induced regulatory T cell genes 
(including Foxp3) 28 days after transplantation.
48
 This was observed at the time of full donor 
engraftment suggesting that these putative CD4
+
CD25
+
 Treg cells were of donor origin. In 
this study, up-regulation of regulatory T cell genes was associated with the absence of GvHD 
despite donor effector cell administration.
48
 All these data including those on the prevention 
of GvHD
5-6
 and our findings highlight the in vivo donor Treg induction/expansion as a 
promising approach to prevent the deleterious alloreactivity after HC transplantation. 
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In conclusion, apoptotic cell infusion enhances BM engraftment by a TGF-β-dependent 
mechanism that leads to Treg expansion. For the first time to our knowledge, a link between 
apoptotic cells and Treg expansion is reported. This could be an additional mechanism to 
immunomodulatory cytokine production
19,25-29
 or cross-tolerization
20-22
 to prevent deleterious 
responses against dying cells during normal turnover. We propose to take advantage of this 
physiological mechanism that maintains self-tolerance to improve HC transplantation 
outcomes. 
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MATERIALS AND METHODS 
Mice 
Specific pathogen-free 5- to 6-week old male FVB (H-2
q
), C57BL/6 (H-2
b
) and BALB/c (H-
2
d
) mice (Janvier, Genest-St-Isle, France) were kept in quarantine for at least one week before 
BM transplantation (BMT). CD11c/DTR/eGFP transgenic mice from a BALB/c background 
(kindly provided by S. Jung, The Weizmann Institute of Science, Rehovot, Israel) were bred 
in our animal facility. This transgenic model allows short-term ablation of DC in vivo after 
administration of diphtheria toxin (DT, 100 ng per mouse, Sigma, Saint Quentin Fallavier, 
France) without affecting macrophages.
34
 Mice were given ad libitum access to food and 
water. Neomycin sulfate (1.1 g/L, Demavic, Longvic, France) was added to their drinking 
water as of d–1 of BMT to reduce the risk of infection. Experiments were performed 
according to institutional guidelines. 
 
Antibodies 
The following mAb were used (all obtained from BD PharMingen, San Diego, CA, except 
when stated): FITC-labeled anti-H-2
q
 (KH114, mouse IgG2a), CD8 (53-6.7, rat IgG2a), 
CD11c (HL3, Armenian hamster IgG), CD19 (1D3, rat IgG2a), CD25 (7D4, rat IgM), 
CD45RB/B220 (RA3-6B2, rat IgG2a), Sca-1 (D7, Rat IgG2a), PE-labeled anti-I-A
b
 
(M5/114.15.2, rat IgG2a, reacts also with I-A
d
, I-E
d
, I-E
k
 and I-A
q
), H-2
d
 (SF1-1.1, mouse 
IgG2a), CD25 (3C7, rat IgG1 or PC61, rat IgG1), CD62L (MEL-14, rat IgG2a), CD117 (2B8, 
rat IgG2b), CD152 (UC10-4F10-11, Armenian hamster IgG), PE-cyanin 5-labelled F4/80 
(A3-1, rat IgG2b, Serotec, Oxford, UK), peridinin chlorophyll-a protein (PerCP)-conjugated 
anti-CD4 (RM4-5, rat IgG2a), anti-CD3 (145-2C11, hamster IgG1), PerCP cyanin 5.5-
conjugated anti-H-2
d
 (SF1-1.1), CD11b (M1/70, rat IgG2b) and allophycocyanin (APC) 
conjugated-anti-CD3 (145-2C11). Azide-free low endotoxin purified anti-CD25 (3C7, rat 
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IgG2b or PC61, rat IgG1) or control (irrelevant) Abs (BD PharMingen) and anti-pan TGF- 
(rabbit IgGs) or rabbit IgGs (Sigma) were used in vivo. 
 
Cell preparation 
Donor BM cells from FVB or C57BL/6 mice and splenocytes from BALB/c, C57BL/6 or 
FVB mice were prepared as described.
31,35
 After isolation procedures, cell viability was 
always greater than 90% by Trypan Blue (Sigma) dye exclusion. Sca-1
+
 cell-enriched grafts 
were obtained by immunomagnetic cell sorting (Miltenyi Biotec, Paris, France) from 
C57BL/6 BM cells according to the manufacturer's instructions. Purity assessed by Sca-1 
mAb staining was > 80% and donor BM phagocyte depletion assessed by CD11c and F4/80 
mAb staining was > 83%. Splenocyte apoptosis was induced by a 40-Gray dose of -
irradiation 6 h before infusion to allow apoptotic changes to occur.
31
 Apoptosis was 
confirmed by FITC-conjugated Annexin-V (Beckman Coulter Immunotech, Marseille, 
France) and flow cytometry as well as Hoechst 33342 (Molecular Probes, Eugene, OR) 
staining and UV microscopy. Absence of secondary necrosis was documented using Trypan 
Blue staining just before infusion. At time of infusion, spleen cells were mainly early-stage 
apoptotic cells (70-85% of cells were Annexin-V positive and propidium iodide negative; less 
than 10% of cells were propidium iodide positive).
31
 Splenic CD62L
+
CD4
+
CD25
+
 T cells 
were sorted using an EPICS ALTRA cell sorter (Beckman Coulter Immunotech). The purity 
achieved was >95% and staining these cells did not alter their suppressive function. These 
purified CD4
+
CD25
+
 T cells were used for in vitro assays and RNA extraction for quantitative 
real time PCR (QRT-PCR). 
 
Bone marrow transplantation 
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BALB/c recipients were exposed to a sublethal single dose (6 Gy at a rate of 2.7 Gy/min) of 
TBI 16 h before BMT. After, they were given a single i.v. infusion, via a caudal vein, 
containing a limited number of FVB or C57BL/6 BM cells (10
6
) or Sca-1
+
 cell-enriched graft 
(10
5
) alone or with apoptotic splenocytes (5 x 10
6
) of various origins (recipient, donor or 
third-party mice). Both hematopoietic grafts and conditioning regimens were defined to favor 
autologous reconstitution and not engraftment.
31
 Preliminary experiments indicated that a 
minimum of 10
6
 apoptotic spleen cells were required to favor engraftment. The number of 
apoptotic spleen cells used exceeds this minimum number of cells by a factor of 5. In these 
conditions (i.e., i.v. infusion of 5 x 10
6
 early-stage apoptotic spleen cells simultaneously with 
BM grafts), no autoimmunity was observed.
37
 To study the effects of donor apoptotic cell 
infusion on the prevention of acute GvHD, we used a lethal dose of TBI (8 Gy) and a higher 
number of donor BM cells (10
7
) as well as donor viable splenic T cells (3 x 10
6
 to trigger 
GvHD).
51
 Increasing numbers of donor apoptotic spleen cells (2 x 10
6
, 2 x 10
7
 or 10
8
) was 
infused. No immunosuppressive agents were given at any time. 
 
Antibody treatment 
Mice were given 150 µg anti-pan TGF-β Ab or rabbit IgGs by tail vein injection on d0 
(simultaneously with the graft) and on day 3.
35
 CD25 cells were depleted by anti-CD25 mAb 
infusion (8.5 mg/kg or 250 µg/mouse) on day 0 and day 3. Treatment efficiency was 
confirmed by a significant decrease in circulating CD4
+
CD25
+
 T cells (12 + 3 cells/µL, n=3) 
as compared to control mAb-treated mice (227 + 25 cells/µL, n=3, P<0.01, Student t test). 
 
Host phagocyte depletion 
Host phagocyte depletion was performed using clodronate-loaded liposome administration. 
Liposome preparation and i.v. infusion were performed as described.
32,33
 Briefly, liposomes 
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consisting of phosphatidyl choline and cholesterol (Sigma) in 6:1 molar ratio were 
resuspended in PBS and injected via the tail vein (final volume of 0.2 ml containing about 2 
mg of clodronate-loaded liposomes). The day after, mice were irradiated and grafted as 
described above. Host phagocyte depletion was controlled 20 h after treatment, on two treated 
mice in each experiment, by immunohistochemistry and cytometry analysis. Spleens were 
removed, cut (5-µm sections), mounted on microscope slides and air dried for staining. After 
endogenous phosphatase quenching by levamisole solution (DakoCytomation, Glostrup, 
Denmark) and
 
nonspecific site blocking, sections were stained with purified CD11b (M1/70), 
CD11c (HL3) or control Ab (BD PharMingen) and revealed by biotinylated-conjugated
 
goat 
anti-rat or anti-Armenian hamster Ab (Jackson ImmunoResearch, West Grove, PA) followed 
by a streptavidin/alkaline phosphatase complex (DakoCytomation). Then, a solution of 
fuchsine substrate chromogen (DakoCytomation) was added. Hematoxylin was used as a 
counterstain. 
 
Bone marrow engraftment 
Detection of engraftment was performed by flow cytometry
31,35
 using H-2 specific mAb on 
peripheral blood cells and at week 7 or 9 post-BMT on splenic cells. Analysis was performed 
with a FACSCalibur
TM
 (BD Biosciences, San Jose, CA) using CellQuest® software (Becton 
Dickinson) or a CyAn LX
TM
 (DakoCytomation) using Summit® software (DakoCytomation). 
Recipients were considered as engrafted when they presented at least 15% of cells expressing 
BM donor H-2.
31
 
 
Tracking of fluorescent apoptotic cells 
Apoptotic cells (5 x 10
6
) were labeled using either green PKH67 dye (Sigma) or 5,6-
carboxyfluorescein diacetate succimidyl ester
52
 (CFSE, Molecular Probes, Eugene, OR) 
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before apoptosis induction according to the manufacturer's instructions. After staining and 
induction of apoptosis (40 Gy), fluorescent-labeled apoptotic cells were transplanted as 
previously described with the BM graft in 6-Gy-irradiated recipients. After 30, 45 min, 1, 2, 4 
and 8 hrs, mice were CO2-euthanized; spleen, liver and lungs were harvested to perform 
fluorescent-labeled apoptotic cell tracking. Cells from each organ were stained using PE-
conjugated anti-CD11c and PE-cyanin 5-conjugated anti-F4/80 mAb and analyzed by 
cytometry. 
 
Phenotypic analysis of T-cell subsets 
T-cell subsets from blood, spleen, thymus, BM and LN were analyzed after BMT using 
specific mAb staining and cytometry. For intracytoplasmic staining, cells were stained with 
CD3, CD4 and CD25 mAb, fixed in 0.25% paraformaldehyde (Sigma) in PBS and 
permeabilized in saponin solution (Sigma) prior to staining
 
with CD152 mAb. Absolute 
counts of circulating lymphocyte subsets were determined using a single-platform approach 
based on cytometry and tubes containing a defined number of microbeads (TruCOUNT®, BD 
Biosciences).
53
 
 
Ex vivo functional analysis of CD4
+
CD25
+
 T cells 
Functional characterization of CD4
+
CD25
+
 T cells was performed using two mixed leukocyte 
reaction (MLR) assays due to limited material and to avoid pooling spleens from separate 
experimented mice. In the first assay, we depleted CD25
+
 cells among CD4
+
 T cells using 
complement-dependent cytotoxicity (CDC) and compared CD25-depleted vs non-depleted 
splenic CD4
+
 T cell proliferation after allogeneic stimulation. In the second assay, we added 
FACS-sorted splenic CD4
+
CD25
+
 T cells to MLR assays. Spleens from naive FVB (donor 
origin) or C57BL/6 (third-party origin) mice were 40-Gy irradiated and used as stimulator 
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cells in both assays. In the first assay, splenic CD4
+
 T cells from BMT recipients (isolated at 
week 7 post-BMT) were used as responder cells and cultured for 2 h in complete medium 
containing DMEM supplemented with 10% of heat-inactivated FCS (BioWhittaker, Verviers, 
Belgium), 5 x 10
-5
 M 2-ME, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml 
streptomycin (Sigma). Non-adherent responder cells were washed and incubated for 20 min 
with purified either anti-CD25 mAb (3C7) or control IgG2a and then with newborn rabbit 
complement (EFS B/FC, Besançon, France) for 1 h under agitation at room temperature. After 
washing, lysis was repeated for 30 min. CD25 depletion was confirmed by cytometry (< 0.7 
% CD4
+
CD25
+
 T cells after CDC). CD25-depleted or control responder cells were stimulated 
in MLR assays in 96-well round-bottom plates (Sarstedt, Orsay, France) in triplicates for 5 
days in complete medium at 37°C in a 5% CO2 incubator. After a 5-d stimulation, cells were 
pulsed with 1µCi of [methyl-3H]-thymidine (NEN life Science Products, Boston, MA). After 
approximately 16 h of additional culture, cells were harvested and radioactivity was counted 
in a beta scintillation counter (Wallac Betaplate counter, Perkin-Elmer, Norwalk, CT). In the 
second assay, FACS-sorted CD4
+
 CD25
+
 T cells were added to CD25-depleted responder 
cells from naive BALB/c mice stimulated by allogeneic cells, as described above. To 
determine the mechanism(s) by which FACS-sorted CD4
+
CD25
+
 T cells exert their 
suppressive activity, we added CD4
+
CD25
+
 T cells above a cell culture insert (0.3 µm, BD 
Biosciences). We also investigated the neutralizing effect of various Abs at a final 
concentration of 5 µg/ml: anti-pan TGF-β polyclonal Ab, its control Ab (Sigma), anti-IL-10R 
(1B1.2, kindly provided by K. Moore, DNAX Research Institute, Palo Alto, CA, via H. 
Groux, Nice, France), its control mAb (Rat IgG1 mAb, GL113). 
 
Quantitative Real-Time PCR (QRT-PCR) for Foxp3 mRNA 
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Total RNA was extracted using RNA extraction kit (Qiagen, Valencia, CA) according to the 
manufacturer's instructions and reverse transcribed using random hexamers and M-MLV 
reverse transcriptase (Life Technologies, Rockville, MD) to use as a template for QRT-PCR. 
QRT-PCR reactions were then performed in duplicates using gene specific probes and 
universal master mix (Qiagen) on an iCycler iQ thermocycler (Bio-Rad Laboratories, Marnes-
la-Coquette, France). Primers and dual labeled fluorescent probes were designed using Primer 
Express® software (Applied Biosystems, Forster City, CA) to be specific for RNA but not for 
genomic DNA. Primer pairs and related probes were as follow (sense, anti-sense and probe 
respectively): Foxp3: 5'-CCCACCTACAGGCCCTTCTC-3', 5'-
GGCATGGGCATCCACAGT-3' and 5'-FAM-
GGACAGACCACACTTCATGCATCAGCTC-TAMRA-3'; GAPDH (used as endogenous 
reference): 5'-TTCACCACCATGGAGAAGGC-3', 5'-GGCATGGACTGTGGTCATGA-3' 
and 5'-FAM-TGCATCCTGCACCACCAACTGCTTAG-TAMRA-3'. For each sequence, a 
standard curve was generated with a dilution series of a known copy number of the target. The 
relative amount of each unknown sample was determined automatically with the iCycler iQ® 
software, using the threshold cycle (Ct). Data were expressed as normalized Foxp3 mRNA 
expression, which was obtained by dividing the relative amount of Foxp3 mRNA for each 
sample by the relative amount of GAPDH mRNA of the same sample. 
 
Statistical analysis 
Group comparisons of continuous data were made by Student's t or Mann-Whitney Rank Sum 
test. Survival data were analyzed using Kaplan-Maier survival analysis. P-values < 0.05 were 
considered as significant. 
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FIGURE LEGENDS 
Figure 1 Recipient macrophages are mainly involved in the graft-facilitating effect of 
apoptotic spleen cell infusion. (a) Green-PKH- or CFSE-labeled apoptotic cells (detectable in 
the FL1 channel) were used to explore phagocytes involved in the apoptotic cell uptake. Left 
panel: 45 min after BMT, fluorescent apoptotic cells infused simultaneously with BM graft 
were found in splenic DC (F4/80
low
CD11c
+
FL1
+
; white arrows) as well as in macrophages 
(F4/80
high
CD11c
-
FL1
+
; black arrows). Results from a representative experiment out of 4. 
Middle panel: non-fluorescent apoptotic cells used as controls. Right panel: kinetics of the 
appearance of CFSE
+
CD11c
+
 DC (■) and CFSE+F4/80+ macrophages (●) after infusion of 
CFSE-labeled apoptotic cells. The percentage of CFSE
+
 cells contained within the indicated 
splenic cell population is listed on the y axis. n = 3 mice per time point. Bars represent S.D. 
(b) Sca-1 cell sorting was used to deplete phagocytes from the BM (left panel: a 
representative sorting experiment out of 4). Right panel: donor engraftment after infusion of 
total C57BL/6 BM (10
6
 cells) or sca-1-enriched graft (Sca-1, 10
5
 cells) with (Apo cells, 
hatched bars) or without (white bars) apoptotic cells. Pooled results from 3 independent 
experiments (at least 20 mice/group) expressed in % of engrafted mice. * P < 0.05. (c) 
Clodronate-loaded liposomes were infused before BMT to deplete host splenic phagocyting 
cells. Left panel: flow cytometric CD11b staining shows the effective depletion of CD11b
+
 
macrophages at day 3 after clodronate-liposome infusion. CD11b staining in PBS loaded-
liposome treated mice was shown as control. Right panel: donor engraftment after infusion of 
total BM (10
6
 cells) with (hatched bars) or without (white bars) apoptotic cells in mice treated 
by PBS-liposomes or clodronate-liposomes. (d) Recipient CD11c
+
 DC were depleted at day-1 
before BMT using a single infusion of diphtheria toxin (DT). Top panel: a representative 
depletion of eGFP
+
CD11c
+
 cells after a 20 h DT treatment. Bottom panel: donor engraftment 
after infusion of total BM (10
6
 cells) with (hatched bars) or without (open bars) apoptotic cells 
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in DT-treated transgenic mice. Pooled results from 2 independent experiments expressed in % 
of engrafted mice. * P < 0.05. 
 
Figure 2 Apoptotic spleen cell infusion simultaneously with a bone marrow graft induces an 
in vivo TGF-β-dependent splenic expansion of CD4+CD25+ T cells. (a) Splenic CD4+CD25+ 
T cells increase after apoptotic spleen cell infusion. These cells were evaluated by cytometry 
in different groups: naive mice, engrafted and non-engrafted mice given apoptotic cells, 
engrafted mice given only a higher number of BM cells (3 x 10
6
) and engrafted mice given a 
higher conditioning regimen (7 Gy). Boxes represent mean + SEM, bars the S.D. and circles 
the highest and lowest values. *: P < 0.01. (b) TGF-β neutralization inhibits apoptotic spleen 
cell-induced splenic CD4
+
CD25
+
 T cell increase. The percentage of splenic CD4
+
CD25
+
 T 
cells was evaluated 7-9 weeks post-graft in TGF-β mAb-treated mice (n = 7) vs in irrelevant 
isotype Ab-treated mice (n= 9). Pooled results of 2 independent experiments. *: P < 0.01. 
 
Figure 3 Apoptotic spleen cell infusion simultaneously with a bone marrow graft induces in 
vivo splenic expansion of CD4
+
CD25
+
 regulatory T cells expressing high levels of Foxp3 
mRNA and exhibiting in vitro cell-to-cell contact-dependent suppression. (a) Expanded 
splenic CD4
+
CD25
+
 T cells from engrafted and non-engrafted mice were characterized 7-9 
weeks post-BMT. CD25,  H-2
d
 and CD62L expressions were evaluated on the CD4
+
CD3
+
 T 
cell gate (CD3+ ; CD4+ ; SSC vs FSC), whereas intracellular CTLA-4 expression was 
evaluated on the CD3
+
CD4
+
CD25
+
 T cell gate. (b) Seven to nine weeks post-BMT, cell-
sorted splenic CD4
+
CD25
+
 T cells were analyzed for Foxp3 mRNA expression in engrafted (n 
= 2, hatched bars) and non-engrafted (n = 1, open bar) mice that had been given apoptotic 
cells plus BM cells. Relative Foxp3 mRNA expression was obtained by dividing relative 
Foxp3 expression in the CD4
+
CD25
+
 T cell fraction by that of the CD4
+
CD25
-
 T cell fraction. 
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(c) Foxp3 mRNA expression is assessed in whole spleen of either mice given BM alone (left 
open bars, n= 4), mice given apoptotic cells plus BM (hatched bars, n= 6) 7-9 week post-
BMT. Foxp3 mRNA expression in the spleen of naive BALB/c mice (right open bars, n= 8) 
was shown as control. Results are expressed as mean + SEM of normalized Foxp3 expression 
(obtained by dividing the relative amount of Foxp3 mRNA for each sample by the relative 
amount of GAPDH mRNA of the same sample). (d) Splenic CD4
+
 T cells from engrafted (left 
panel, n = 3) or non-engrafted (right panel, n = 2) BALB/c mice given donor FVB BM and 
apoptotic cells were cultured with or without allogeneic (FVB donor or C57BL/6 third party) 
stimulator cells. T cells were CD25-depleted (open bars) or not (hatched bars). MLR 
proliferation was assessed by [
3
H]thymidine uptake (cpm). *: P < 0.01. (e) Cell-sorted 
CD4
+
CD25
+
 T cells were added to a MLR between stimulator irradiated splenic FVB donor 
cells and CD25-depleted responder BALB/c recipient CD4
+
 T cells (n = 2) with or without 
(Ø) anti-IL10R, anti-TGF-β mAb or both. A transwell was also used to separate the MLR 
from sorted CD4
+
CD25
+
 T cells. Results are expressed as relative proliferation obtained by 
dividing the CD4
+
 T cell proliferation in response to allogeneic stimulators by the 
proliferation obtained in similar conditions but in the presence of blocking Abs or transwell. 
[
3
H]thymidine uptake > 9000 cpm. *: P < 0.05. 
 
Figure 4 Depletion of CD11c
+
 dendritic cells has no effect on CD62L
high
CD4
+
CD25
+
 T cell 
increase induced by apoptotic spleen cell infusion. Recipient CD11c
+
 DC were depleted at 
day -1 before BMT using a single infusion of diphtheria toxin (DT). CD11c/eGFP/DTR 
transgenic mice given donor apoptotic cells plus BM were treated (left box, n= 8) or not (right 
box, n= 5) with DT. CD62L
+
CD4
+
CD25
+
 T cells were analyzed by cytometry 7-9 weeks post-
BMT. Boxes represent mean + SEM, bars the SD. 
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Figure 5 Apoptotic spleen cell infusion simultaneously with a bone marrow graft induces an 
early increase of CD62L
+
CD4
+
CD25
+
 T cells of both host and donor origin. (a) Host 
macrophages are involved in the early increase of CD62L
+
CD4
+
CD25
+
 T cells induced by 
apoptotic spleen cell infusion. Splenic CD62L
+
CD4
+
CD25
+
 T cells were analyzed by 
cytometry at different time points after the infusion of FVB BM alone (□, n=5), or FVB BM 
plus FVB apoptotic cells (■, n=5). Such cells were also analyzed in BALB/c mice pre-treated 
with clodronate-liposomes and grafted with FVB BM plus FVB apoptotic cells (▲, n=3) and 
in irradiated BALB/c mice (∆, n = 3). *: P < 0.05. (b) Percentage of donor 
CD62L
+
CD4
+
CD25
+
 T cells in the spleen of mice given FVB BM alone  (□, n=5) or BM plus 
apoptotic spleen cells (■, n=5) at different early time points after BMT. *: P < 0.05. 
 
Figure 6 CD25
+
 cell depletion significantly reduces the number of circulating donor-derived 
cells after apoptotic spleen cell infusion. Percentage of donor-derived cells was evaluated 7-9 
week post-graft in the spleen of mice given only BM (●, n=10), BM and apoptotic cells plus 
anti-CD25 mAb (▲, n=10) or plus irrelevant mAb (■, n=12). Number of engrafted mice in 
each group was shown. Dotted line indicates 15% of donor-derived cells corresponding to 
engraftment. Pooled results of 2 independent experiments. *: P < 0.05. 
 
Figure 7 CD25
+
 cell depletion prevents the protecting effect of donor apoptotic spleen cell 
administration on graft-versus-host disease occurrence.(a) Cumulative survival was assessed 
in the GvHD model in mice receiving BM plus splenic T cells and donor apoptotic spleen 
cells (▲) or not (control GvHD group; □). Mice receiving BM alone (●) or only lethally 
irradiated (○) were also used as control. Results of a representative experiment out of 4 are 
expressed in % of cumulative survival. (b) Donor apoptotic spleen cells delays lethal GvHD 
occurrence in a dose-dependent manner. Median survival time was assessed in mice receiving 
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increasing number of apoptotic cells (2 x 10
6
, 2 x 10
7
 or 10
8
 apoptotic spleen cells; hatched 
bars) or not (GvHD Ctrl group; open bar) in addition to BM and splenic T cells. Pooled 
results from 4 independent experiments (10 mice per group, excepted for ctrl group n= 5) are 
expressed in median survival time (day) + SD. (c) Delayed CD25
+
 cell depletion abolishes the 
protective effects of donor apoptotic spleen cell infusion on lethal GvHD occurrence. 
Cumulative survival was assessed in mice receiving BM plus splenic T cells (GvHD Ctrl 
group, □); with apoptotic cells and treated at day 3 and 6 by anti-CD25 mAb (●) or irrelevant 
IgG1 control (■). Results of a representative experiment out of 3 are expressed in % of 
cumulative survival. 10 mice per group. 
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Supplement Figure 1: 
Clodronate-loaded liposomes infused before BMT deplete host splenic phagocytes. (a) A representative staining 
of splenic phagocytes using anti-CD11c and CD11b antibodies, 24 hours after the infusion of PBS-loaded 
liposomes or clodronate-loaded liposomes. (b) Left panels: immuno-histological CD11b staining shows the 
effective depletion of CD11b
+
 macrophages in the recipient spleen 12 h after clodronate-liposome infusion (top 
panel). A CD11b staining was observed when PBS-liposomes were infused (bottom panel) (magnified: 10X). 
Right panels: immuno-histological CD11c staining reveals that not all splenic DC subsets were depleted by 
clodronate-loaded liposome infusion, due to their anatomic location, as previously reported (Leenen, P. J., K. 
Radosevic, J. S. Voerman, B. Salomon, N. van Rooijen, D. Klatzmann, and W. van Ewijk. 1998. Heterogeneity 
of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and 
subpopulation turnover. J Immunol 160:2166). 
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